Filtered By:
Source: Journal of Diabetes Investigation
Drug: Empagliflozin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 4 results found since Jan 2013.
Empagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in routine care in East Asia: Results from the EMPRISE study
ConclusionsThe results suggest that both empagliflozin and SGLT2i compared with DPP-4i are associated with a lower risk of cardiovascular events and all-cause mortality in routine clinical care in East Asia.
Source: Journal of Diabetes Investigation - January 31, 2023 Category: Endocrinology Authors: Dae Jung Kim,
Wayne H ‐H Sheu,
Wook‐Jin Chung,
Daisuke Yabe,
Kyoung Hwa Ha,
Masaomi Nangaku,
Elise Chia‐Hui Tan,
Koichi Node,
Atsutaka Yasui,
Weiyu Lei,
Sunwoo Lee,
Laura Saarelainen,
Anouk Deruaz‐Luyet,
Moe H Kyaw,
Yutaka Seino,
EM Tags: ORIGINAL ARTICLE Source Type: research
Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
ConclusionsThe incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial.
Source: Journal of Diabetes Investigation - January 29, 2021 Category: Endocrinology Authors: Shun Kohsaka,
Hiraku Kumamaru,
Shiori Nishimura,
Satoshi Shoji,
Eiji Nakatani,
Nao Ichihara,
Hiroyuki Yamamoto,
Yoshiki Miyachi,
Hiroaki Miyata Tags: Original Article Source Type: research